

Amendments to the Specification:

Please replace the paragraph at page 14, from line 1 through line 3, with the following paragraph:


--of average molecular mass 1,810 and whose sequence was determined to be Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln (SEQ ID NO: 2).—

Please replace the paragraph at page 15, from line 1 through line 12, with the following paragraph:

-- banks although it was found to bear some resemblance with those of dynorphins, especially dynorphin A (Fig. 6). The structural homologies between this novel peptide and dynorphin A support the idea that the former may interact with the ORL1 receptor as the latter does with the kappaopioid receptor [12, 13, 15]. In particular, the novel peptide may be viewed as made up of a N-terminal Phe-Gly-Gly-Phe (residues 1-4 of SEQ ID NO: 2) "message" for biological activity, followed by a Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys (residues 5-13 of SEQ ID NO: 2) "address", for enhanced potency[15] . The "address" contains all the basic amino acid residues that are anticipated to bind the acidic second exofacial loop of the ORL1 receptor.--

Respectfully submitted,

Date: January 5, 2005



Name: Matthew Beaudet
Registration No.: 50,649
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel.: (617) 239-0100